HSP90 Inhibition Without Heat Shock Response

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2018 Jul 21

PMID 30026301

Citations 2

Authors

John C Byrd

Affiliations

Soon will be listed here.

Citing Articles

Plant-Based HSP90 Inhibitors in Breast Cancer Models: A Systematic Review.

Zarguan I, Ghoul S, Belayachi L, Benjouad A Int J Mol Sci. 2024; 25(10).

PMID: 38791506 PMC: 11122155. DOI: 10.3390/ijms25105468.

Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio--arylacetamides as novel HSP90 C-terminal inhibitors.

Liu Y, Li C, Li Y, Zhang S, Zhang N, Bian X J Enzyme Inhib Med Chem. 2023; 39(1):2290912.

PMID: 38083866 PMC: 11721760. DOI: 10.1080/14756366.2023.2290912.

From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition.

Pugh K, Zhang Z, Wang J, Xu X, Munthali V, Zuo A ACS Med Chem Lett. 2020; 11(8):1535-1538.

PMID: 32832020 PMC: 7429967. DOI: 10.1021/acsmedchemlett.0c00100.

References

Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone M . Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 2005; 7(5):457-68. DOI: 10.1016/j.ccr.2005.03.035. View

Johnson M, Yu H, Hart E, Weitner B, Rademaker A, Patel J . Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J Clin Oncol. 2015; 33(15):1666-73. PMC: 4881377. DOI: 10.1200/JCO.2014.59.7328. View

Lancet J, Gojo I, Burton M, Quinn M, Tighe S, Kersey K . Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010; 24(4):699-705. DOI: 10.1038/leu.2009.292. View

Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B . Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood. 2018; 132(3):307-320. PMC: 6225350. DOI: 10.1182/blood-2017-10-810986. View

Hertlein E, Wagner A, Jones J, Lin T, Maddocks K, Towns 3rd W . 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010; 116(1):45-53. PMC: 2904580. DOI: 10.1182/blood-2010-01-263756. View

Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm M, Fritz L . A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003; 425(6956):407-10. DOI: 10.1038/nature01913. View

Walker A, Klisovic R, Johnston J, Jiang Y, Geyer S, Kefauver C . Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2012; 54(9):1996-2002. PMC: 3860322. DOI: 10.3109/10428194.2012.760733. View

Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D . Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood. 2007; 110(2):678-85. PMC: 1924476. DOI: 10.1182/blood-2006-10-054098. View

Shiotsu Y, Neckers L, Wortman I, An W, Schulte T, Soga S . Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood. 2000; 96(6):2284-91. View

10.

Infante J, Weiss G, Jones S, Tibes R, Bauer T, Bendell J . Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. Eur J Cancer. 2014; 50(17):2897-904. DOI: 10.1016/j.ejca.2014.07.017. View